Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Finlabo SIM Spa
|
$58.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Bayer Gets EU Green Light to Market Jaydess Contraceptive-DJ
Dow Jones reported that Bayer AG has received the green light in Europe to market its new long-term contraceptive dubbed Jaydess. Health authorities in the European Union member states will grant national approvals soon. The product is likely to be launched in the European Union second quarter of 2013. Bayer SA has also submitted a marketing application in the United States for the new low dose levonorgestrel-releasing intrauterine system.
Latest Developments for Bayer AG
- Bayer AG To Acquire Herbal Medicine Maker Steigerwald Arzneimittelwerk GmbH-Reuters
- Bayer AG Gets FDA Approval For Advanced Prostate Cancer Drug; Bayer AG And Algeta ASA To Co-Promote Xofigo in United States-DJ
- Bayer AG's Bayer HealthCare LLC To Acquire Conceptus, Inc
- Bayer AG Confirms FY 2013 Sales Guidance
Latest Key Developments in Pharmaceuticals
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb From Warburg Pincus LLC-Reuters
- Valeant Pharmaceuticals International Inc Near Deal To Acquire Bausch & Lomb-Reuters
- Astec LifeSciences Ltd Recommends Dividend; Announces Appointment Of Statutory Auditors
- J B Chemicals and Pharmaceuticals Ltd Recommends Dividend
- Share this
- Link this
- Digg this
Follow Reuters